Related Experiment Videos
How much does it cost to preserve a larynx? An economic study
1Department of Otolaryngology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain.
Summary
Induction chemotherapy for advanced laryngeal cancer is more expensive than total laryngectomy but spares the larynx in 46% of patients. This organ-preservation strategy offers a valuable alternative despite the increased cost.
Area of Science:
- Otolaryngology
- Oncology
- Health Economics
Background:
- Advanced laryngeal cancer treatment often involves difficult choices between organ preservation and radical surgery.
- Induction chemotherapy is increasingly used, but its comparative cost-effectiveness against total laryngectomy is not well-established.
- Previous studies suggest increased costs with induction chemotherapy but lack direct economic comparison for laryngeal cancer.
Purpose of the Study:
- To compare the treatment costs and survival outcomes of total laryngectomy versus induction chemotherapy for advanced laryngeal cancer.
- To evaluate the economic implications of induction chemotherapy as part of an organ-preservation strategy.
Main Methods:
- Retrospective study of 96 patients with T3N0-1 glottic carcinoma.
- Comparison of average treatment costs and adjusted 5-year survival rates.
- Analysis of laryngectomy-sparing rates in the induction chemotherapy group.
Main Results:
- Average cost: 5,853 Eur for total laryngectomy vs. 6,452 Eur for induction chemotherapy.
- Adjusted 5-year survival: 80% for total laryngectomy vs. 72% for induction chemotherapy.
- 46% of patients receiving induction chemotherapy were spared laryngectomy.
Conclusions:
- Induction chemotherapy represents a higher initial cost (approx. 600 Eur increase) compared to total laryngectomy.
- Despite higher costs, induction chemotherapy is a crucial consideration for organ preservation in advanced laryngeal cancer.
- The potential to avoid laryngectomy justifies the economic evaluation of induction chemotherapy.